Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurynas Mockeliunas

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis TreatmentLina Keutzer, Laurynas Mockeliunas, Marieke G G Sturkenboom, et al.
Vaccines|March 28, 2024
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus PandemicLaurynas Mockeliunas, Rob C van Wijk, Caryn M Upton, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 4, 2023
Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modelingRob C van Wijk, Laurynas Mockeliunas, Caryn M Upton, et al.
Scientific Reports|September 28, 2023
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19Rob C van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, et al.
Pharmaceutics|April 23, 2022
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant TuberculosisLaurynas Mockeliunas, Lina Keutzer, Marieke G G Sturkenboom, et al.
Frontiers in Pharmacology|May 1, 2023
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug developmentLaurynas Mockeliunas, Alan Faraj, Rob C van Wijk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2025
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary TuberculosisVeronique de Jager, Laurynas Mockeliunas, Huifang You, et al.
Eclinicalmedicine|May 18, 2022
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trialCaryn M Upton, Rob C van Wijk, Laurynas Mockeliunas, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis TreatmentLina Keutzer, Laurynas Mockeliunas, Marieke G G Sturkenboom, et al.
Vaccines|March 28, 2024
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus PandemicLaurynas Mockeliunas, Rob C van Wijk, Caryn M Upton, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 4, 2023
Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modelingRob C van Wijk, Laurynas Mockeliunas, Caryn M Upton, et al.
Scientific Reports|September 28, 2023
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19Rob C van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, et al.
Pharmaceutics|April 23, 2022
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant TuberculosisLaurynas Mockeliunas, Lina Keutzer, Marieke G G Sturkenboom, et al.
Frontiers in Pharmacology|May 1, 2023
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug developmentLaurynas Mockeliunas, Alan Faraj, Rob C van Wijk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2025
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary TuberculosisVeronique de Jager, Laurynas Mockeliunas, Huifang You, et al.
Eclinicalmedicine|May 18, 2022
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trialCaryn M Upton, Rob C van Wijk, Laurynas Mockeliunas, et al.
Pageof 1